-
Mashup Score: 1
In a unique study, doctors at Fred Hutch want to find out whether a 100-year old tuberculosis vaccine known as BCG — made of live but hobbled cousins of the TB germs that afflict humans — might safely work as a stand-in for real TB in future trials to assess new drugs and better vaccines to stop the disease.
Source: Fred HutchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Vignesh Packiam, MD, discusses study results showing sequential intravesical gemcitabine and docetaxel is an effective and well-tolerated therapy for BCG-naïve NMIBC.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 1Dr. Packiam on background of study of sequential intravesical chemo in BCG-naïve NMIBC - 2 year(s) ago
Vignesh Packiam, MD, explains how innovation driven by the BCG shortage led to a potential promising new regimen of sequential intravesical gemcitabine and docetaxel for patients with BCG-naïve non–muscle-invasive bladder cancer.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0Multiple BCG vaccinations for prevention of COVID-19 and other infectious diseases in Type 1 diabetes - 2 year(s) ago
In a randomized, double-blinded, placebo-controlled, Phase 2/3 trial, Faustman et al. investigate the safety and efficacy of multiple doses of the >100-year old Bacille-Calmette-Guerin (BCG) vaccine against COVID-19. They also determine vaccine efficacy against other infectious diseases, which if present would suggest platform protection against new SARS-CoV-2 variants.
Source: Cell Reports MedicineCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 1
Read the current issue of The Lancet Global Health, a monthly open access journal publishing robustly designed original research on all aspects of global health
Source: www.thelancet.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0ADC/ICI Combo Effective in BCG-Unresponsive NMIBC - 2 year(s) ago
Results from a phase 3 study of pembrolizumab and nadofaragene firadenovec in patients with BCG-unresponsive non–muscle invasive bladder cancer suggests that immune checkpoint inhibitors have synergy with antibody drug conjugates.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1The bilious solution of Monsieurs Calmette et Guérin - 2 year(s) ago
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). This month’s history story was inspired by a question from one of my ‘check cystoscopy’ patients, “Mr Goddard, tell me again, why did you put TB in my bladder to cure my cancer?” My standard reply to this is, “Well, in the olden days they found…
Source: Urology NewsCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 1
Inoculation of Mycobacterium bovis Bacille Calmette-Guérin (BCG) in the skin mobilizes local dendritic cells (DC) to the draining lymph node (dLN) in a process that remains incompletely understood. In this study, a mouse model of BCG skin infection was used to investigate mechanisms of skin DC
Source: The Journal of ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0
A biologics license application has been submitted to the FDA for N-803 plus Bacillus Calmette-Guérin as treatment for patients with BCG-unresponsive non-muscle invasive bladder cancer in situ with or without Ta or T1 disease.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1EAU NMIBC Risk Calculator - 2 year(s) ago
This app estimates the probability of a Non–muscle Invasive Bladder Cancer (NMIBC) patient’s progression to MIBC after trans-urethral resection of bladder tumours (TURBT) and calculates their updated European Association of Urology (EAU) Prognostic Factor Risk Group. It Incorporates both the WHO 2004/2016 and WHO 1973 Grading Classification Systems and is based on the following…
Source: nmibc.netCategories: Latest Headlines, UrologyTweet
In a unique study, doctors at Fred Hutch want to find out whether a 100-year-old #tuberculosisvaccine known as #BCG might safely work as a stand-in for real #TB in future trials to assess new drugs and better vaccines to stop the disease. Read more: https://t.co/SUrxIF2qYL